Insulet (NASDAQ:PODD) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Insulet (NASDAQ:PODD) from a hold rating to a buy rating in a research note published on Saturday morning,Wall Street Zen reports.

Other equities analysts also recently issued research reports about the stock. Barclays raised their target price on shares of Insulet from $150.00 to $165.00 and gave the company an “equal weight” rating in a research note on Friday. JPMorgan Chase & Co. boosted their price target on Insulet from $152.00 to $170.00 and gave the stock a “neutral” rating in a research report on Thursday. Raymond James Financial restated an “outperform” rating and issued a $180.00 price target on shares of Insulet in a research note on Thursday, August 6th. Royal Bank Of Canada raised their price objective on Insulet from $160.00 to $180.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Truist Financial lowered Insulet from a “buy” rating to a “hold” rating and reduced their price objective for the company from $210.00 to $153.00 in a research report on Wednesday, August 5th. Twelve investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $185.38.

Insulet Stock Performance

Shares of PODD stock opened at $146.51 on Friday. The company’s fifty day moving average price is $141.97 and its 200-day moving average price is $176.65. The stock has a market cap of $10.16 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 1.08 and a beta of 1.06. The company has a current ratio of 2.51, a quick ratio of 1.83 and a debt-to-equity ratio of 0.60. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.59 by $0.40. The company had revenue of $842.00 million during the quarter, compared to analyst estimates of $832.63 million. Insulet had a net margin of 13.44% and a return on equity of 31.76%. Insulet’s quarterly revenue was up 19.2% compared to the same quarter last year. During the same period last year, the business earned $1.24 EPS. On average, equities analysts expect that Insulet will post 6.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Insulet during the second quarter valued at approximately $1,018,582,000. Arrowstreet Capital Limited Partnership increased its position in shares of Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after acquiring an additional 1,011,369 shares in the last quarter. Man Group plc bought a new stake in shares of Insulet during the second quarter valued at approximately $78,746,000. Amundi increased its position in shares of Insulet by 13.6% during the second quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock valued at $77,320,000 after acquiring an additional 60,929 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of Insulet during the second quarter valued at approximately $64,921,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

Insulet Company Profile

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps.

Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Insulet serves customers in the United States and international markets.